Search

Your search keyword '"K., Grilusová"' showing total 5 results
Start Over Author "K., Grilusová"
5 results on '"K., Grilusová"'

1. Cancer-associated thrombosis – treatment and prevention with direct oral factor Xa inhibitors

Author

K, Grilusová, T, Bolek, I, Škorňová, J, Staško, M, Samoš, and M, Mokáň

Subjects
Pyridines, Pyridones, Administration, Oral, Thrombosis, Venous Thromboembolism, Heparin, Low-Molecular-Weight, Thiazoles, Fibrinolytic Agents, Rivaroxaban, Oncology, Neoplasms, Humans, Pyrazoles, Factor Xa Inhibitors
Abstract

Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in patients with cancer. Moreover, management of VTE is frequently connected with complications, namely risk of recurrent VTE and bleeding. Low molecular weight heparins (LMWH) therapy administrated for 3-6 months is currently considered a standard for the treatment of cancer-associated VTE (CA-VTE). Direct oral factor Xa inhibitors (FXaI) apixaban, edoxaban and rivaroxaban have emerged as a new possibility for long-term antithrombotic therapy for VTE. These agents expose several advantages in individuals with cancer, and might overcome several disadvantages connected with LMWH therapy.First clinical studies with oral FXaI for the treatment of CA-VTE with very promising results were recently published. The article summarizes current data regarding the use of oral FXaI in the treatment of CA-VTE.

Published
2021
Full Text
View/download PDF

3. Anti-Xa Activity-Guided Edoxaban Therapy for Cancer-Associated Venous Thromboembolism?

Author

Samoš M, Bolek T, Škorňová I, Benko J, Stančiaková L, Grilusová K, Galajda P, Stasko J, Kubisz P, and Mokáň M

Subjects
Humans, Anticoagulants therapeutic use, Pyridines therapeutic use, Factor Xa Inhibitors therapeutic use, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Neoplasms complications
Abstract

Competing Interests: The authors have no conflicts of interest to declare.

Published
2022
Full Text
View/download PDF

4. Apixaban: An Optimal Agent for the Treatment of Cancer-Associated Venous Thromboembolism?

Author

Grilusová K, Bolek T, Škorňová I, Stančiaková L, Mikušová V, Kubisz P, Galajda P, Staško J, Samoš M, and Mokáň M

Subjects
Anticoagulants adverse effects, Humans, Pyrazoles adverse effects, Pyridones adverse effects, Neoplasms complications, Neoplasms drug therapy, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Venous Thromboembolism prevention & control
Abstract

Background: Apixaban, a direct inhibitor of activated coagulation factor X (FXaI), is being frequently selected for treatment and prevention of venous thromboembolism (VTE). Several reports about possible use of oral FXaI in patients with cancer-associated VTE (CA-VTE) have been published recently., Areas of Uncertainty: The efficacy/safety profile of oral FXaI anticoagulation in patients with CA-VTE seems promising; however, several problems remain unanswered. The pharmacologic profile of apixaban could prefer this agent for the treatment of CA-VTE., Data Sources: Currently available medical literature was searched and reviewed to summarize data regarding the use of apixaban for the prevention and treatment of cancer-associated VTE., Results: Apixaban therapy in patients with cancer and VTE is expected to increase as clinicians gain more experience and reassurance with data from real-world studies that are generally promising. Several studies demonstrated that apixaban exhibits noninferiority to warfarin and low molecular weight heparin in preventing recurrent thrombosis in cancer-associated VTE. Nevertheless, there are still concerns regarding the bleeding associated with apixaban therapy, and regarding the optimal management of these bleeding emergencies., Therapeutic Opinion: Although currently available evidence confirms the noninferiority of apixaban for reduction of the risk of recurrent VTE in patients with cancer; there are still concerns regarding the safety, especially in selected subpopulations of these patients., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

5. The impact of atorvastatin on dabigatran plasma levels in patients with atrial fibrillation.

Author

Bolek T, Samoš M, Stančiaková L, Škorňová I, Grilusová K, Galajda P, Staško J, Kubisz P, and Mokáň M

Subjects
Aged, Antithrombins therapeutic use, Atrial Fibrillation blood, Dabigatran therapeutic use, Female, Humans, Male, Pilot Projects, Anticholesteremic Agents therapeutic use, Antithrombins blood, Atorvastatin therapeutic use, Atrial Fibrillation drug therapy, Dabigatran blood
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results